ライフサイエンスコーパス: hematopoietic neoplasm

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ty has been implicated in the development of hematopoietic neoplasms.

2 5-mC and 5-hmC patterns are common events in hematopoietic neoplasms.

3 tion, and, ultimately, to HSC exhaustion and hematopoietic neoplasms.

4 re syndromes, myelodysplastic syndromes, and hematopoietic neoplasms.

5 ctivation is a prominent oncogenic driver of hematopoietic neoplasms.

6 romosomal translocation is a common theme in hematopoietic neoplasms.

7 mors, has not been fully elucidated in human hematopoietic neoplasms.

8 and communicate about mouse models of human hematopoietic neoplasms.

9 nationally recognized for their expertise in hematopoietic neoplasms.

10 e classification of lymphoid and nonlymphoid hematopoietic neoplasms.

11 this mechanism has been described mostly in hematopoietic neoplasms.

12 mors, has not been fully elucidated in human hematopoietic neoplasms.

13 l models of localized and disseminated human hematopoietic neoplasms.

14 herefore, seems to be a progression event in hematopoietic neoplasms.

15 or (ER) gene, is frequently altered in human hematopoietic neoplasms.

16 7)Lu-DOTATATE: 8 patients (2.9%) developed a hematopoietic neoplasm (4 MDS, 1 AML, 1 MPN, and 2 MDS/M

17 delineated as early as 3 months post-TBI for hematopoietic neoplasms, 6 months for solid neoplasms, a

18 be an important step in the genesis of human hematopoietic neoplasms and might be a useful molecular

19 Cells from hematopoietic neoplasms appear in this limited sample to

20 The expected number of hematopoietic neoplasms based on The Netherlands Cancer

21 eukemia (BCR-ABL1(+) B-ALL) is an aggressive hematopoietic neoplasm characterized by a block in diffe

22 on in both conditions and also occurs in the hematopoietic neoplasm hairy cell leukemia (HCL).

23 enotypic, and molecular features of a unique hematopoietic neoplasm in these mice.

24 MYC is an important oncogene in hematopoietic neoplasms in humans, yet the mechanism by

25 hat the critical inactivation event in these hematopoietic neoplasms is elimination of p19(Arf), and

26 The development of hematopoietic neoplasms is often associated with mutatio

27 Tempol reduced the incidence of hematopoietic neoplasms (lymphomas) in both strains, whe

28 ands Cancer Registry, the expected number of hematopoietic neoplasms (MDS, AML, MPN, and MDS/MPN) was

29 It is proposed here that nonlymphoid hematopoietic neoplasms of mice be classified in 4 broad

30 ficacy of existing drugs in treating defined hematopoietic neoplasms, paired with promising new data

31 iseases and neoplasms (MPN), a collection of hematopoietic neoplasms regarded as preleukemic, thereby

32 d apoptosis and therefore clinical trials in hematopoietic neoplasms should be of high priority.

33 y that VEGF may play a role in the growth of hematopoietic neoplasms such as multiple myeloma through

34 ears to be gaining a place in the therapy of hematopoietic neoplasms, such as non-Hodgkin's lymphoma,

35 ized the need for a classification of murine hematopoietic neoplasms that would allow investigators t

36 The relative risk for developing a hematopoietic neoplasm was 2.7.

37 ility, and the development of transplantable hematopoietic neoplasms with myeloproliferation.

38 rative neoplasms (MPNs) are a set of chronic hematopoietic neoplasms with overlapping clinical and mo

39 M) and mast cell leukemia (MCL) are advanced hematopoietic neoplasms with poor prognosis.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。